Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 6/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25734753 | 0.90 | DNM2 (0.46) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL30151348 | 0.90 | DNM2 (0.46) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL19900231 | 0.90 | DNM2 (0.46) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL22851306 | 0.88 | KMT2A (0.47) | DNM2HTR2CMCHR2MCHR1RAB9A | |
| SCHEMBL22851628 | 0.88 | MCHR1 (0.44) | HTR2CMCHR2MCHR1NPC1KMT2A | |
| SCHEMBL23761839 | 0.87 | DNM2 (0.47) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL25858274 | 0.87 | DNM2 (0.45) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL25734765 | 0.87 | DNM2 (0.45) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL22851622 | 0.87 | PRMT3 (0.43) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL30151359 | 0.87 | IMPDH2 (0.53) | DNM2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | DNM2 736/4885HTR2C 3524/4885MCHR2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.